BioSpace News Archive

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury, today announced that it will host a webcast to discuss its Q3 2023 business highlights.

Inari Medical, Inc. announced that it will release its third quarter 2023 financial results on Wednesday, November 1, 2023.

Cellipont Bioservices and Evia Bio announced today a strategic partnership to launch a Cryopreservation Excellence Center (CryoX) at Cellipont Bioservices cGMP cell therapy manufacturing facilities in The Woodlands, TX (Houston) in 2024.

NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) today announced that an abstract related to comprehensive results from the company’s Phase 2b ALPINE4 trial of aldafermin in patients with compensated cirrhosis (liver fibrosis stage 4, or, F4) due to nonalcoholic steatohepatitis (NASH) has been selected for an oral plenary presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, which will take place November 10-14, 2023, in Boston, MA.

Miromatrix Medical Inc. (NASDAQ: MIRO) today announced that it will be presenting at the 2023 International Society for Organ Donation and Procurement (“ISODP”) Organ Donation Congress in Las Vegas, NV on October 18-21 at Mandalay Bay Resort.

Cerevel Therapeutics Holdings, Inc., a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that it has commenced an underwritten public offering of $400.0 million of shares of its common stock.

Exxel Pharma (“Exxel” or the “Company”), an early-stage pharma company working to develop EX937 as a safe and effective treatment for patients suffering from chronic cough, today announced that Soren Mogelsvang, PhD, President and Chief Executive Officer of Exxel will participate in the Virtual Investor Ask the CEO Conference on Tuesday, October 24, 2023 at 3:00 PM ET.

Adolore BioTherapeutics (“Adolore” or the “Company”), a company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, today announced that Roelof Rongen, CEO of Adolore, will participate at the Virtual Investor Ask the CEO Conference on Wednesday, October 25, 2023 at 3:00 PM ET.

eGenesis, a biotechnology company developing human-compatible (HuCo™) organs for the treatment of organ failure, today announced publication in the journal Nature of long-term survival data from a proof-of-concept study evaluating engineered porcine donor kidneys transplanted into a cynomolgus macaque model.

MicuRx Pharmaceuticals, Inc. announces that a poster on our preclinical product, MRX-6038, will be presented at ID Week entitled “In vitro Potency of a Leucyl-tRNA Synthetase Inhibitor, MRX-6038, Against Mycobacterium tuberculosis, Mycobacterium avium, and Mycobacterium abscessus.”